Vyriad Announces Oral Presentation at the 65th American Society of Hematology Annual Meeting
09 Nov 2023
ImmunotherapyASHCell TherapyClinical Study
ROCHESTER, Minn., Nov. 9, 2023 /PRNewswire/ -- Vyriad, Inc., a clinical-stage biotechnology company developing the next generation of targeted genetic therapies, today announced that its abstract, In Vivo Generation of Functional CD19 CAR-T Cells Using a Serum-Stable CD3-Targeted Lentiviral Vector, has been selected for an oral presentation at the 65th American Society of Hematology Annual Meeting to be held December 9-12, 2023, in San Diego, California. Vyriad's presentation will discuss progress in developing its highly targeted, efficient, serum-stable and durable lentiviral vector technology to deliver genetic payloads directly and specifically to CD3+ T cells.
Presentation Title: In Vivo Generation of Functional CD19 CAR-T Cells Using a Serum-Stable CD3-Targeted Lentiviral Vector
Session Name: Cellular Immunotherapies: Basic and Translational: Exploring Novel Platforms for Next-Gen CAR-based Therapies
Presentation Date/Time: Monday, December 11, at 11:30 a.m. PT
Presenting Speaker: Stephen J. Russell, M.D., Ph.D., Chief Executive Officer
Full abstracts are available for online viewing via the ASH Annual Meeting website at www.Hematology.org.
About Vyriad, Inc.
Vyriad is a clinical-stage biotechnology company developing the next generation of targeted genetic therapies using engineered viruses, viral vectors and viral envelope glycoproteins to deliver genes directly to targeted cells. This targeting technology facilitates oncolytic virotherapy, in vivo gene therapies and gene editing applications. Phase 1-2 trials with our oncolytic viruses, both as monotherapies and in combination with immune-oncology drugs, are underway in multiple cancer indications in collaboration with Regeneron, Mayo Clinic and other research and medical institutions. Vyriad is a privately held company based in Rochester, Minnesota. For more information, visit www.vyriad.com.
Vyriad Media Contact:
Scott Beck
[email protected]
SOURCE Vyriad, Inc.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.